PCDH17 Antibody, FITC conjugated

1. Methylation of PCDH17 could play an important role in development and progression of high-grade serous ovarian carcinoma (HGSOC)and has potential to become a target in the search for new clinical biomarkers PMID: 29991130
2. PCDH17 methylation in serum is a potential prognostic biomarker for patients with renal cell carcinoma after surgery. PMID: 28688232
3. PCDH17 functions as a tumor suppressor inhibiting Wnt/beta-catenin signaling and metastasis in breast cancer but is frequently methylated in primary tumors which could be a potential biomarker. PMID: 27351130
4. Aberrant methylation of protocadherin 17 is associated with acute lymphoblastic leukemia. PMID: 27643535
5. PCDH-17 inhibited metastasis via EGFR/MEK/ERK signaling pathway. PMID: 26386721
6. DNA methylation in a combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting bladder cancer effectively among pathologically varied sample groups. PMID: 26700620
7. PCDH17 methylation in serum is a frequent event in early-stage prostate cancer, and it is an independent predictor of BCR after radical prostatectomy PMID: 26683656
8. PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in clear cell renal cell carcinoma patients PMID: 26404644
9. PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. PMID: 24567353
10. PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer PMID: 24366498
11. This study demonistrated that critical role for PCDH17 in the synaptic development of specific corticobasal ganglia circuits and suggest the involvement of PCDH17 in such circuits in depressive behaviors. PMID: 23684785
12. PCDH17 acts as a tumour suppressor, exerting its anti-proliferative activity through inducing apoptosis and autophagy, and is frequently silenced in gastric and colorectal cancers. PMID: 22926751
13. Our study clearly demonstrates that PCDH17 is transcriptionally downregulated in gastric cancer due to aberrant promoter CpG island methylation PMID: 22207556
14. statistical significant downregulation of PCDH17/PCH68 and PTPRD was observed PMID: 21213369
15. results suggest that silencing of PCDH17 expression through hypermethylation of the promoter or other mechanisms leads to loss of its tumour-suppressive activity, which may be a factor in the carcinogenesis of a subgroup of ESCCs PMID: 20200074
16. Azoospermic testis showed down-regulation of CDH18 and PCDH17. PMID: 20180417
17. the apparent occurrence of an unusual TG 3' splice site in intron 2 is discussed PMID: 17672918

Show More

Hide All

HGNC: 14267

OMIM: 611760

KEGG: hsa:27253

UniGene: Hs.106511